Active, not recruitingPhase 3NCT04544293

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Studying Autoimmune pulmonary alveolar proteinosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Savara Inc.
Principal Investigator
Bruce Trapnell, MD, MD
Children's Hospital Medical Center, Cincinnati
Intervention
Molgramostim(drug)
Enrollment
164 enrolled
Eligibility
18 years · All sexes
Timeline
20212027

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04544293 on ClinicalTrials.gov

Other trials for Autoimmune pulmonary alveolar proteinosis

Additional recruiting or active studies for the same condition.

See all trials for Autoimmune pulmonary alveolar proteinosis

← Back to all trials